4-(4-(pyrimidin-2-yl)piperazin-1-yl)benzaldehyde | 179488-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-(pyrimidin-2-yl)piperazin-1-yl)benzaldehyde
• 英文别名: 4-(4-pyrimidin-2-ylpiperazin-1-yl)benzaldehyde
• CAS: 179488-71-2
• 化学式: C₁₅H₁₆N₄O
• 分子量: 268.318
• InChiKey: ZGFDQEGXXRILCS-UHFFFAOYSA-N

物化性质

• 沸点：
  509.8±60.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  49.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-(pyrimidin-2-yl)piperazin-1-yl)benzaldehyde 在 sodium cyanoborohydride 、 溶剂黄146 、 苯甲醚 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 (2S)-benzenesulfonylamino-3-[methyl-[4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzyl]-amino]-propionic acid
  参考文献：
  名称：

  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activity

  摘要：

  In order to generate novel compounds with integrin alpha(v)beta(3)-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective alpha(IIb)beta(3) antagonists, replacement of piperazine with piperidine furnished a potent alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonist. Structureactivity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.060
• 作为产物：
  描述：

  4-(1-哌嗪基)苯甲酸乙酯 在 manganese(IV) oxide 、 二异丁基氢化铝 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 7.5h， 生成 4-(4-(pyrimidin-2-yl)piperazin-1-yl)benzaldehyde
  参考文献：
  名称：

  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activity

  摘要：

  In order to generate novel compounds with integrin alpha(v)beta(3)-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective alpha(IIb)beta(3) antagonists, replacement of piperazine with piperidine furnished a potent alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonist. Structureactivity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.060

文献信息

• Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity
  作者：Uday Kiran Velagapudi、Marie-France Langelier、Cristina Delgado-Martin、Morgan E. Diolaiti、Sietske Bakker、Alan Ashworth、Bhargav A. Patel、Xuwei Shao、John M. Pascal、Tanaji T. Talele

  DOI：10.1021/acs.jmedchem.8b01709

  日期：2019.6.13

  Poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors are a class of anticancer drugs that block the catalytic activity of PARP proteins. Optimization of our lead compound 1 (( Z)-2-benzylidene-3-oxo-2,3-dihydrobenzofuran-7-carboxamide; PARP-1 IC50 = 434 nM) led to a tetrazolyl analogue (51, IC50 = 35 nM) with improved inhibition. Isosteric replacement of the tetrazole ring with a carboxyl

  聚腺苷5'-二磷酸核糖）聚合酶（PARP）抑制剂是一类抗癌药物，可阻断PARP蛋白的催化活性。优化我们的先导化合物1（（Z）-2-亚苄基-3-氧代-2,3-二氢苯并呋喃-7-羧酰胺; PARP-1 IC50 = 434 nM）产生了四唑基类似物（51，IC50 = 35 nM）具有更好的抑制作用。用羧基等位取代四唑环（60，IC50 = 68 nM）产生了有希望的新先导，随后对其进行了优化，以获得具有有效PARP-1 IC50值（4-197 nM）的类似物。PARP酶谱分析显示，大多数化合物对PARP-2具有选择性，其IC50值可与临床抑制剂媲美。与PARP-1结合的关键抑制剂的X射线晶体结构说明了与向PARP-1腺苷结合袋延伸的类似附件的相互作用方式。化合物81，一种同工型选择性PARP-1 / -2（IC50 = 30 nM / 2 nM）抑制剂，与同基因BRCA1精制细胞相比，对乳腺
• Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer’s disease
  作者：Chandra Bhushan Mishra、Apra Manral、Shikha Kumari、Vikas Saini、Manisha Tiwari

  DOI：10.1016/j.bmc.2016.06.027

  日期：2016.8

  A series of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)-1H-indene-1,3(2H)-diones were designed, synthesized and appraised as multifunctional anti-Alzheimer agents. In vitro studies of compounds 27–38 showed that these compounds exhibit moderate to excellent AChE, BuChE and Aβ aggregation inhibitory activity. Notably, compounds 34 and 38 appeared as most active multifunctional agents in the

  设计，合成和评价了一系列新型的2-（4-（4-取代的哌嗪-1-基）亚苄基）-1 H-茚-1,3（2 H）-二酮作为多功能抗阿尔茨海默病药物。化合物27 – 38的体外研究表明，这些化合物具有中等至极好的AChE，BuChE和Aβ聚集抑制活性。值得注意的是，化合物34和38在整个系列中是最具活性的多功能剂，并且对AChE表现出优异的抑制作用（IC 50  = 0.048μM：34 ; 0.036μM：38），Aβ聚集（最大抑制百分比为82.2％，IC 50  = 9.2） μM：34; 最大抑制百分比为80.9％，IC 50  = 10.11μM：38），并且在ORAC-FL分析中显示出显着的抗氧化潜能。两种化合物还成功减少了SH-SY5Y细胞中H 2 O 2诱导的氧化应激。令人着迷的是，化合物34和38在SH-SY5Y细胞中对H 2 O 2和Aβ诱导的毒性表现出了令人钦佩的神经保护作用。另
• Design, synthesis, in silico and biological evaluation of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)hydrazine carboxamides
  作者：Shikha Kumari、Chandra Bhushan Mishra、Danish Idrees、Amresh Prakash、Rajesh Yadav、Md. Imtaiyaz Hassan、Manisha Tiwari

  DOI：10.1007/s11030-016-9714-7

  日期：2017.2

  A series of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)hydrazinecarboxamide derivatives has been successfully designed and synthesized to evaluate their potential as carbonic anhydrase (CA) inhibitors. The inhibitory potential of synthesized compounds against human CAI and CAII was evaluated. Compounds 3a–n exhibited \(\hbox IC}_50}\) values between \(1.89-}415.1\,\upmu \hbox M}\) against

  已经成功设计并合成了一系列新型的2-（4-（4-取代的哌嗪-1-基）亚苄基）肼甲酰胺衍生物，以评估其作为碳酸酐酶（CA）抑制剂的潜力。评估了合成化合物对人CAI和CAII的抑制潜力。化合物3A-N显示出\（\ hbox中IC} _ 50} \）之间的值\（1.89 - } 415.1 \，\ upmu \ hbox中M} \）对CAI和\（0.62 - } 66.9 \， \ upmu \ hbox M} \）针对CAII。化合物3g是活性最高的抑制剂，对CAII的\（\ hbox IC} _ 50} \）值为\（0.62 \，\ upmu \ hbox M} \）。化合物3g的分子对接研究带有CAII的化合物显示该化合物非常适合CAII的活性位点，并且与锌离子（\（\ hbox Zn} ^ 2 +} \））以及活性位点上的三个组氨酸残基相互作用。与CAII配合的
• Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal
  作者：Chandra Bhushan Mishra、Shikha Kumari、Andrea Angeli、Silvia Bua、Martina Buonanno、Simona Maria Monti、Manisha Tiwari、Claudiu T. Supuran

  DOI：10.1016/j.ejmech.2018.07.019

  日期：2018.8

  We report the design, synthesis and pharmacological assessment of novel benzenesulfonamide derivatives acting as effective carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. All the synthesized compounds were screened for their CA inhibitory action against four isoforms of human origin (h), i.e. hCA I, hCA II, hCA VII and hCA IX. In-vitro carbonic anhydrase inhibition studies have shown that first series

  我们报告新型苯磺酰胺衍生物作为有效的碳酸酐酶（CA，EC 4.2.1.1）抑制剂的设计，合成和药理学评估。筛选所有合成的化合物对人类起源的四种同工型（h），即hCA I，hCA II，hCA VII和hCA IX的CA抑制作用。体外碳酸酐酶抑制研究表明，第一个系列的4-（2-（4-（4-（4-取代的哌嗪-1-基）亚苄基）肼基）苯磺酰胺（4a-4i）使低纳摩尔范围的分子对中等纳摩尔范围的抑制剂具有抗hCA II和hCA VII有效参与了癫痫发生。此外，属于第二系列的化合物4-（2-（4-（4-取代的哌嗪基）亚苄基）肼基羰基）苯磺酰胺（8a-8k）对hCA VII表现出有效的抑制作用，对其他hCA亚型的抑制作用较弱。借助获得的CA抑制结果，我们选择了一些有效的hCA II和hCA VII抑制剂（4g，4i和8d）来测试其在瑞士白化病雄性小鼠中对MES和sc-PTZ癫痫发作试验的抗惊厥功效。结果
• Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease
  作者：Chandra Bhushan Mishra、Shikha Kumari、Apra Manral、Amresh Prakash、Vikas Saini、Andrew M. Lynn、Manisha Tiwari

  DOI：10.1016/j.ejmech.2016.09.057

  日期：2017.1

  antioxidant activity. Among the entire series compounds IP-9, IP-13 and IP-15 appeared as most active multi-functional agents and displayed marked AChE inhibitory, Aβ disaggregation and antioxidant activity. Studies indicate that IP-13 and IP-15 showed better AChE inhibitory activity than the standard drug donepezil and IP-9, IP-13 as well as IP-15 exhibited better Aβ aggregation inhibitory activity than

  一种基于多奈哌齐的新型多功能剂“（E）-5,6-二甲氧基-2-（4-（4-取代的哌嗪-1-基）亚苄基）-2,3-二氢-1 H-茚满-已经设计并合成了“ 1-ones”作为潜在的抗阿尔茨海默氏病药物。体外研究表明，这些化合物显示出中等至良好的AChE和Aβ聚集抑制活性。这些衍生物还具有令人赞叹的抗氧化活性。在整个系列化合物中，IP-9，IP-13和IP-15是最活跃的多功能剂，并显示出显着的AChE抑制，Aβ分解和抗氧化活性。研究表明IP-13和IP-15表现出比标准药物多奈哌齐更好的AChE抑制活性，IP-9，IP-13和IP-15表现出比姜黄素更好的Aβ聚集抑制活性。这些化合物（IP-9，IP-13和IP-15）成功地减轻了H 2 O 2诱导的SH-SY5Y细胞的氧化应激，并表现出出色的针对H 2 O 2的神经保护活性。以及Aβ以浓度依赖性方式诱导SH-SY5Y细胞的毒性。而且，在细胞毒